Current Status of Implementation of Self-Administration Training in Various Regions of Europe, Canada and the USA in the Management of Hereditary Angioedema

被引:33
作者
Caballero, T. [1 ]
Sala-Cunill, A. [2 ]
Cancian, M. [3 ]
Craig, T. J. [5 ]
Neri, S. [4 ]
Keith, P. K. [6 ]
Boccon-Gibod, I. [7 ]
Bethune, C. [8 ]
Bork, K. [9 ]
机构
[1] Hosp La Paz, Inst Hlth Res IdiPaz, ES-28046 Madrid, Spain
[2] Univ Barcelona, Barcelona, Spain
[3] Univ Padua, Padua, Italy
[4] Catania Univ, Catania, Italy
[5] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA
[6] McMaster Univ, Hamilton, ON, Canada
[7] Grenoble Univ Hosp, Dept Internal Med, Natl Reference Ctr Angioedema, Grenoble, France
[8] Derriford Hosp, Plymouth PL6 8DH, Devon, England
[9] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
关键词
Hereditary angioedema; Self-administration; Current status; Benefits; Quality of life; C1 INHIBITOR DEFICIENCY; C1-INHIBITOR CONCENTRATE; ATTACKS; GUIDELINES; ICATIBANT; EFFICACY; PATIENT;
D O I
10.1159/000351233
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Results from a 16-question survey about self-administration of hereditary angioedema (HAE) therapy, administered in Europe, Canada and the USA, were used to guide discussion at an international HAE expert meeting. The aim was to capture information about current practice in self-administered HAE therapy in these countries, including self-administration training, the key benefits of switching to self-administration, the barriers to self-administration and trends in self-administration. Overall, switching to self-administration therapy is looked upon favourably from both patient and clinician perspectives by virtue of the potential improvement in quality of life arising from optimisation of therapy and early intervention. The recent changes to product licences allowing self-administration provide additional options for the management of HAE. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码:10 / 16
页数:7
相关论文
共 24 条
  • [1] Safety and efficacy of icatibant self-administration for acute hereditary angioedema
    Boccon-Gibod, I.
    Bouillet, L.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 168 (03) : 303 - 307
  • [2] Efficacy of C1-Inhibitor Concentrate (Berinert®) for the Treatment of Cutaneous Attacks of Acute Hereditary Angioedema Compared to Historical Untreated Controls
    Bork, Konrad
    Staubach, Petra
    Bernstein, Jonathan A.
    Feuersenger, Henrike
    Machnig, Thomas
    Craig, Timothy J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB31 - AB31
  • [3] Current Management Options for Hereditary Angioedema
    Bork, Konrad
    [J]. CURRENT ALLERGY AND ASTHMA REPORTS, 2012, 12 (04) : 273 - 280
  • [4] 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
    Tom Bowen
    Marco Cicardi
    Henriette Farkas
    Konrad Bork
    Hilary J Longhurst
    Bruce Zuraw
    Emel Aygoeren-Pürsün
    Timothy Craig
    Karen Binkley
    Jacques Hebert
    Bruce Ritchie
    Laurence Bouillet
    Stephen Betschel
    Della Cogar
    John Dean
    Ramachand Devaraj
    Azza Hamed
    Palinder Kamra
    Paul K Keith
    Gina Lacuesta
    Eric Leith
    Harriet Lyons
    Sean Mace
    Barbara Mako
    Doris Neurath
    Man-Chiu Poon
    Georges-Etienne Rivard
    Robert Schellenberg
    Dereth Rowan
    Anne Rowe
    Donald Stark
    Smeeksha Sur
    Ellie Tsai
    Richard Warrington
    Susan Waserman
    Rohan Ameratunga
    Jonathan Bernstein
    Janne Björkander
    Kristylea Brosz
    John Brosz
    Anette Bygum
    Teresa Caballero
    Mike Frank
    George Fust
    George Harmat
    Amin Kanani
    Wolfhart Kreuz
    Marcel Levi
    Henry Li
    Inmaculada Martinez-Saguer
    [J]. Allergy, Asthma & Clinical Immunology, 6 (1)
  • [5] Challenges of C1-Inhibitor Concentrate Self-Administration
    Boysen, H. B.
    Bouillet, L.
    Aygoeren-Puersuen, E.
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2013, 161 : 21 - 25
  • [6] Hereditary angio-oedema in Denmark: a nationwide survey
    Bygum, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) : 1153 - 1158
  • [7] Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema
    Caballero, T
    López-Serrano, C
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : 476 - 477
  • [8] Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration
    Cicardi, M.
    Craig, T. J.
    Martinez-Saguer, I.
    Hebert, J.
    Longhurst, H. J.
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2013, 161 : 3 - 9
  • [9] Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group
    Cicardi, M.
    Bork, K.
    Caballero, T.
    Craig, T.
    Li, H. H.
    Longhurst, H.
    Reshef, A.
    Zuraw, B.
    [J]. ALLERGY, 2012, 67 (02) : 147 - 157
  • [10] Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema
    Cicardi, M.
    Banerji, A.
    Bracho, F.
    Malbran, A.
    Rosenkranz, B.
    Riedl, M.
    Bork, K.
    Lumry, W.
    Aberer, W.
    Bier, H.
    Bas, M.
    Greve, J.
    Hoffmann, T. K.
    Farkas, H.
    Reshef, A.
    Ritchie, B.
    Yang, W.
    Grabbe, J.
    Kivity, S.
    Kreuz, W.
    Levy, R. J.
    Luger, T.
    Obtulowicz, K.
    Schmid-Grendelmeier, P.
    Bull, C.
    Sitkauskiene, B.
    Smith, W. B.
    Toubi, E.
    Werner, S.
    Anne, S.
    Bjorkander, J.
    Bouillet, L.
    Cillari, E.
    Hurewitz, D.
    Jacobson, K. W.
    Katelaris, C. H.
    Maurer, M.
    Merk, H.
    Bernstein, J. A.
    Feighery, C.
    Floccard, B.
    Gleich, G.
    Hebert, J.
    Kaatz, M.
    Keith, P.
    Kirkpatrick, C. H.
    Langton, D.
    Martin, L.
    Pichler, C.
    Resnick, D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (06) : 532 - 541